Auro-Rufinamide 200 mg (Rufinamide TABLET) 200 MG

AURO-RUFINAMIDE 200 MG tablets are a pharmaceutical product used for managing certain medical conditions. This oral medication is manufactured by AURO PHARMA INC in Canada.

Strength

200 MG

Manufacturer / TM Owner

AURO PHARMA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rufinamide is generally used as an adjunctive therapy for seizure disorders. It is often prescribed to help control seizures in individuals who have not responded adequately to other treatments. The primary purpose of rufinamide is to provide additional seizure control, helping to reduce the frequency and severity of episodes.

Side Effects

Common effects of rufinamide may include dizziness, fatigue, and headache. Some individuals might experience nausea or vomiting. It is important to monitor for any unusual symptoms and consult a healthcare provider if they persist or worsen.

Precautions & Warnings

Rufinamide should be handled with care, especially for individuals with a history of heart conditions or liver issues. It is advisable to follow the prescribed dosage and avoid abrupt discontinuation. Always store the medication in a cool, dry place away from children and pets.

Avoid Interactions

Rufinamide may interact with other medications, particularly those metabolized by the liver. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol should be avoided as it may exacerbate the side effects.

Frequently Asked Questions

Rufinamide is typically used as an adjunctive treatment for seizure disorders, helping to control seizures in individuals who have not responded to other therapies.

Rufinamide tablets are taken orally, usually with or without food. Follow the dosage instructions provided by your healthcare provider.

Common side effects may include dizziness, fatigue, headache, nausea, and vomiting. If these effects are severe or persistent, consult your healthcare provider.

It is generally advised to avoid alcohol while taking rufinamide, as it may increase the risk of side effects.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.